BV200

BV200 is a first-in-class anti-virulence small molecule drug developed by BioVersys. It targets *Staphylococcus aureus* (including methicillin-resistant strains, MRSA) by inhibiting the transcriptional regulator AgrA, which controls the production of key virulence determinants such as alpha-toxin, phenol-soluble modulins (PSM), and Panton-Valentine leukocidin (PVL). By preventing toxin expression rather than killing bacteria directly, BV200 aims to reduce tissue damage, inflammation, and disease progression in conditions like atopic dermatitis and severe infections in hospitalized patients. This approach may help limit infection severity and mortality regardless of antibiotic resistance status. The drug is being developed for use as a topical formulation for skin diseases such as atopic dermatitis and potentially in combination with antibiotics for more severe infections like pneumonia[1][4][7].

Brand names

BV200BV-200BV 200

Other names

BV200BV-200BV 200